In this double-blind , randomised , placebo-controlled trial , we enrolled hypertensive patients , aged 2079 years , with albuminuria ( urinary albumin-to-creatinine ratio [ UACR ] in the first morning void urine of 30599 mg/g ) , an estimated glomerular filtration rate of 50 mL/min per 173 m2 or more , and who had received an angiotensin-converting enzyme inhibitor , an angiotensin receptor blocker , or both , for at least 8 weeks .